Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2023-09-27 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
关于独立董事收回辞职报告的公告
Board/Management Information Classification · 100% confidence The document is an announcement from the company's board regarding the withdrawal of a resignation report by an independent director. It discusses changes in the status of a board member and compliance with relevant laws and regulations. There is no financial data, no report publication, no voting results, and no mention of financial performance or other report types. This fits the category of Board/Management Information, as it concerns changes and updates related to the company's board of directors.
2023-09-27 Chinese
关于增加2023年度日常关联交易预计额度的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the increase in the estimated amount of daily related-party transactions for the year 2023. It includes details about the approval process by the board and independent directors, the nature and amounts of the related-party transactions, the related parties involved, and the impact on the company. The document is a formal announcement of a corporate action related to related-party transactions and their estimated limits, not a financial report or detailed management discussion. It does not contain financial statements or comprehensive financial data but rather focuses on governance and compliance aspects of related-party transactions. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-09-27 Chinese
关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2023 first extraordinary general meeting of shareholders (临时股东大会) for Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It includes details about the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. There is no financial data, earnings, or report content. It is an announcement informing shareholders about the meeting and how to participate, not the actual meeting materials or results. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2023-09-27 Chinese
关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the revision of the company's Articles of Association (公司章程). It details specific changes to governance-related provisions such as the legal representative, powers of the chairman and general manager, and meeting notification methods. The document is a formal announcement of these governance changes and states that the revised Articles will be submitted to the shareholders' meeting for approval. It does not contain financial data, audit information, or detailed management reports. The content focuses on governance structure and internal rules, which aligns with the Governance Information category. The document length is 2069 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Governance Information (CGR).
2023-09-27 Chinese
关于子公司产品碳酸司维拉姆片获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding its subsidiary receiving official drug registration approval from the National Medical Products Administration. It details the drug name, registration classification, approval number, and potential impact on the company. There is no financial data, no mention of financial results, no regulatory certifications, or meeting materials. It is an announcement about a regulatory approval related to product registration, not a financial report or management change. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-09-25 Chinese
海通证券股份有限公司关于上海宣泰医药科技股份有限公司2023年度持续督导半年度跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled '2023年度持续督导半年度跟踪报告' which translates to '2023 Annual Continuous Supervision Semi-Annual Tracking Report'. It is issued by the sponsor (保荐机构) Haitong Securities for the company Shanghai Xuantai Pharmaceutical Technology Co., Ltd. The document details the continuous supervision activities conducted by the sponsor during the first half of 2023, including compliance checks, on-site inspections, information disclosure reviews, and other regulatory oversight tasks. It references regulatory approvals, ongoing monitoring, and specific supervisory actions rather than presenting full financial statements or comprehensive annual or interim financial results. The document is a detailed report on the sponsor's continuous supervision work over a half-year period, which aligns with the definition of an Audit Report / Information (AR) as it relates to regulatory oversight and compliance monitoring rather than a full Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or certification but a substantive supervisory report. Therefore, the appropriate classification is AR (Audit Report / Information). H1 2023
2023-09-07 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.